Salpingectomy vs Tubal Sterilisation in Low Risk for Ovarian Cancer Women and Its Effect on Ovarian Reserve
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Leonidas Magarakis, MD
- Phone Number: 046737529929
- Email: lemagarakis@gmail.com
Study Locations
-
-
Värmaland
-
Karlstad, Värmaland, Sweden, 65185
- Department of Obstetrics and Gynecology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women seeking for tubal sterilisation
Exclusion Criteria:
- women older than 45
- family history of ovarian cancer
- presence of menopausal symptoms
- irregular cycles
- Hormone Replacement Therapy or hormone contraceptions the last 3 months
- history of previous ovarian or uterine surgeries
- imaging suggesting an ovarian cyst or other adnexal pathology during investigation
- previous salpingectomy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Tubal Sterilization with bipolar
Salpingectomy vs Tubal Sterilisation
|
|
|
ACTIVE_COMPARATOR: Bilateral Salpingectomy
Salpingectomy vs Tubal Sterilisation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Anti-Mullerian hormone (AMH)and Follicle Stimulation Hormone (FSH)
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Anti-Mullerian hormone (AMH)
Time Frame: 1 year
|
1 year
|
|
Operative time
Time Frame: Postoperatively
|
Postoperatively
|
|
Complications
Time Frame: 3 months
|
3 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Follicle Stimulation Hormone (FSH)
Time Frame: 3 months
|
3 months
|
|
Follicle Stimulation Hormone (FSH)
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
Other Study ID Numbers
- SEvsTSinAMH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.